| Subject: | FDA Changes Warning and Adverse Reactions for Avastin |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Fri, 29 Sep 2006 - 12:00 am |
| Genentech and the FDA have notified healthcare professionals about revisions to the WARNINGS and ADVERSE REACTIONS sections of the prescribing information of Avastin. Avastin, in combination with intravenous 5-fluorouracil–based chemotherapy, is indicated for first-or second-line treatment of patients with metastatic carcinoma of the colon or rectum. Updates to the prescribing information are intended to inform health care professional of the following:
Cases of a rare... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
REFERENCES:
External Links:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
